NDC 51144-030

PADCEV EJFV

Enfortumab Vedotin

PADCEV EJFV is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Seagen Inc.. The primary component is Enfortumab Vedotin.

Product ID51144-030_0e6ab7c8-66e2-4f5e-b93e-b1e3d59ab859
NDC51144-030
Product TypeHuman Prescription Drug
Proprietary NamePADCEV EJFV
Generic NameEnfortumab Vedotin
Dosage FormInjection, Powder, Lyophilized, For Solution
Route of AdministrationINTRAVENOUS
Marketing Start Date2019-12-18
Marketing CategoryBLA / BLA
Application NumberBLA761137
Labeler NameSEAGEN INC.
Substance NameENFORTUMAB VEDOTIN
Active Ingredient Strength30 mg/3mL
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 51144-030-01

1 VIAL, SINGLE-DOSE in 1 BOX (51144-030-01) > 3 mL in 1 VIAL, SINGLE-DOSE
Marketing Start Date2019-12-18
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 51144-030-01 [51144003001]

PADCEV EJFV INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Marketing CategoryBLA
Application NumberBLA761137
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2019-12-18

Drug Details

Active Ingredients

IngredientStrength
ENFORTUMAB VEDOTIN30 mg/3.3mL

NDC Crossover Matching brand name "PADCEV EJFV" or generic name "Enfortumab Vedotin"

NDCBrand NameGeneric Name
51144-020PADCEVENFORTUMAB VEDOTIN
51144-030PADCEVENFORTUMAB VEDOTIN

Trademark Results [PADCEV]

Mark Image

Registration | Serial
Company
Trademark
Application Date
PADCEV
PADCEV
87869971 not registered Live/Pending
Agensys, Inc.
2018-04-10
PADCEV
PADCEV
87869971 not registered Live/Pending
Seattle Genetics, Inc.
2018-04-10

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.